A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program

VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p.m. ET in Boston

SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Liz Proos, Vice President of Product Development of Daré Bioscience, will present on the Company’s Intelligent Drug Delivery System (DARE-IDDS) at the 16th annual Partnership Opportunities in Drug Delivery (PODD) conference, one of the leading drug delivery industry conferences, taking place October 29–30, 2026 in Boston, MA.

Ms. Proos will present “Expanding Chronic Therapy Adherence with a Single Programmable Device” on Friday, October 30, from 2:30 to 2:50 p.m. ET. The presentation will highlight the potential of DARE-IDDS to address challenges associated with long-term and chronic injection-based therapies by combining programmable drug delivery, wireless communication and dosing flexibility within a single subcutaneously implanted device.

Millions of patients on chronic therapies depend on repeated injections, frequent clinic visits and the discipline to stay on schedule. When patients miss doses, the benefits of even highly effective medicines can be lost. DARE-IDDS is designed to take that burden off the patient.

DARE-IDDS is a single device, implantable under the skin, that is designed to:

• Store and deliver more than 100 discrete doses over periods ranging from months to years
• Program each dose electronically, using independent drug reservoirs and electronic dose control
• Connect wirelessly, with the potential to let patients and healthcare providers monitor and adjust treatment remotely
• Reduce treatment burden, potentially cutting the need for repeated injections, frequent clinic visits and ongoing medication management

By combining extended drug storage with programmable delivery and patient control, DARE-IDDS is being developed to support a range of potential therapeutic applications. The technology is initially being targeted for contraception through Daré Bioscience’s DARE-LARC1 program, which is being developed with the goal of providing a long-acting, reversible contraceptive option designed to give women greater flexibility in managing their reproductive journey. Because DARE-IDDS is a platform, Daré Bioscience believes it may also have applications across other therapeutic areas where adherence, treatment burden and reliable dosing are significant issues, and where future development and commercial partners may see value.

“DARE-IDDS represents an opportunity to rethink how medications are delivered over the long term, particularly in therapeutic areas where adherence and treatment burden can limit the benefits of available therapies,” said Ms. Proos. “By bringing together programmable dosing, wireless connectivity and patient control in a single implantable device platform, we are working to advance a more flexible approach to drug delivery that has the potential to benefit patients, healthcare providers and future development and commercial partners.”

Daré Bioscience has collaborated with Cambridge Consultants, a global product development and technology consultancy, to advance the DARE-IDDS platform, combining drug delivery expertise with capabilities in implantable electronics, connectivity and device engineering. The collaboration reflects Daré Bioscience’s focus on advancing differentiated technology designed to address unmet needs and create new possibilities for patient-centered care.

DARE-IDDS is an investigational device in preclinical development. It has not been approved or cleared for clinical investigation in humans or for any use in humans. The DARE-IDDS features described in this press release are based on the results of technological proof-of-concept studies.

ABOUT DARÉ BIOSCIENCE, INC.

Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.

FORWARD-LOOKING STATEMENTS

Daré Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “prepare,” “progress,” “seek,” “should,” “would,” “build” or the negative version of these words and similar expressions.

In this press release, forward-looking statements include, but are not limited to, statements relating to: the potential capabilities of DARE-IDDS as part of a therapeutic product for humans, including storing and delivering more than 100 discrete doses over periods ranging from months to years, electronic dose programming, and wireless connectivity enabling remote treatment monitoring and adjustment; the potential of DARE-IDDS to improve treatment adherence and reduce treatment burden; the potential application of DARE-IDDS in a broad range of therapeutic areas; the therapeutic and market potential of future products utilizing DARE-IDDS; continued development of DARE-LARC1 and its potential to demonstrate safety and effectiveness as a long-acting reversible contraceptive product; and the potential for Daré Bioscience to enter into strategic collaborations for development and commercialization of therapeutic products utilizing DARE-IDDS.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré Bioscience’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: advancing DARE-LARC1 and any future product candidate utilizing DARE-IDDS through preclinical stage development and into human clinical trials; the ability of product candidates utilizing DARE-IDDS to demonstrate acceptable safety, tolerability and efficacy, including contraceptive effectiveness, in humans; the potential that product candidates utilizing DARE-IDDS may not demonstrate the dose capacity, duration of drug storage and delivery, or wireless connectivity and remote treatment monitoring and adjustment functionality anticipated based on technological proof-of-concept studies of DARE-IDDS; the risk that positive findings in technological proof-of-concept studies, other nonclinical studies and/or early clinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; delays, increased costs, or failure in completing necessary nonclinical and clinical studies of a product candidate, including due to unanticipated requirements for additional testing; potentially more complex, costly or lengthy development and approval requirements for drug-device combination product candidates; delays or failure to obtain U.S. Food and Drug Administration (FDA) or foreign regulatory approval for a product candidate; achieving anticipated treatment adherence or reduction in treatment burden benefits with any DARE-IDDS-based product, if approved; difficulties establishing and maintaining relationships with development and/or commercial collaborators; Daré Bioscience's dependence on third parties to conduct nonclinical and clinical studies and manufacture and supply clinical trial material and commercial product, and the performance and resource commitments of such third parties; difficulties in manufacturing drug product candidates and their components at the required quality, stability and scale for clinical trials and commercialization; Daré Bioscience's ability to obtain additional capital when and as needed to execute its business strategy and continue as a going concern; dependence on grants and other financial awards from governmental entities and a private foundation and the risk that such funding may be reduced, delayed, or terminated, or may be insufficient to advance a product candidate into or through a particular stage of development as anticipated; potential suspension and delisting of Daré Bioscience's common stock from The Nasdaq Capital Market; failure of any products, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; the risk that developments by competitors make Daré Bioscience's products or product candidates less competitive or obsolete; Daré Bioscience's ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré Bioscience's ability to satisfy the monetary obligations and other requirements in connection with its exclusive in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Daré Bioscience's ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré Bioscience's product candidates, which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré Bioscience's products or product candidates or the business activities of Daré Bioscience, its commercial collaborators or other third parties on which Daré Bioscience relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré Bioscience's ability to raise additional capital or on Daré Bioscience's operations, financial results and condition, and ability to achieve current plans and objectives; and cybersecurity incidents or similar events that compromise Daré Bioscience's technology systems and/or significantly disrupt Daré Bioscience's business or those of third parties on which Daré Bioscience relies.

Daré Bioscience’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré Bioscience’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including Daré Bioscience’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contact:
Daré Bioscience Investor Relations
innovations@darebioscience.com

Source: Daré Bioscience, Inc.